© Reuters. FILE PHOTO: A general view of the BioNTech building where the production of the coronavirus disease (COVID-19) vaccine has started in Marburg, Germany, November 18, 2021. REUTERS/Fabian Bimmer
ZURICH (Reuters) – Investment group EQT (NYSE:) and members of the Struengmann family, who are investors in Biontech, are considering a joint bid for Swiss pharmaceutical group Novartis’s generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources.
A potential offer could value Sandoz at more than 20 billion Swiss francs ($21.58 billion), the newspaper reported.
Novartis in October raised the prospect of divesting Sandoz after years of revamping the business, as price pressures mount in the off-patent drug sector.
It said at the time it had begun a strategic review which would “explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for our shareholders”.
The Struengmann family and EQT, who have already made several joint investments, were looking to bring further investors on board as a consortia for a potential deal, Handelsblatt reported.
EQT declined comment. Novartis did not immediately respond to requests by phone and email for comment.
The Swiss drugmaker in 2019 spun off its eyecare division Alcon (NYSE:), marking the largest Swiss stock deal in a decade when it made its debut with a market capitalisation of more than $25 billion.
($1 = 0.9268 Swiss francs)
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
